Last reviewed · How we verify
Vasopressin, Arginine
Arginine vasopressin is a peptide hormone that binds to vasopressin receptors to increase blood pressure, promote water reabsorption in the kidneys, and enhance blood clotting.
Arginine vasopressin is a peptide hormone that binds to vasopressin receptors to increase blood pressure, promote water reabsorption in the kidneys, and enhance blood clotting. Used for Variceal bleeding (esophageal varices), Diabetes insipidus, Hypotension/shock.
At a glance
| Generic name | Vasopressin, Arginine |
|---|---|
| Also known as | Arginine Vasopressin |
| Sponsor | Lars Wiuff Andersen |
| Drug class | Vasopressor agent; antidiuretic hormone |
| Target | Vasopressin receptors (V1a, V1b, V2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Endocrinology; Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Arginine vasopressin (AVP) acts as a potent vasoconstrictor by activating V1 receptors on vascular smooth muscle, thereby increasing systemic vascular resistance and blood pressure. It also binds to V2 receptors in the kidney's collecting duct to increase aquaporin-2 water channel expression, promoting water reabsorption and reducing urine output. Additionally, vasopressin enhances hemostasis by promoting release of von Willebrand factor and factor VIII from endothelial cells.
Approved indications
- Variceal bleeding (esophageal varices)
- Diabetes insipidus
- Hypotension/shock
- Hemophilia A and von Willebrand disease
Common side effects
- Vasoconstriction/ischemia
- Hypertension
- Abdominal cramping
- Nausea
- Headache
- Tremor
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
- Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology (NA)
- Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial) (PHASE3)
- Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (PHASE2)
- Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressin, Arginine CI brief — competitive landscape report
- Vasopressin, Arginine updates RSS · CI watch RSS
- Lars Wiuff Andersen portfolio CI